The cost of CAR T-cell therapy in Europe varies significantly depending on the country, healthcare system, and the specific treatment used. Generally, CAR T-cell therapies are among the most expensive treatments available, reflecting their advanced technology and the complexity of their development and administration. In Europe, two of the most commonly used CAR T-cell therapies are Kymriah and Yescarta, each designed for different types of blood cancers.
In countries like Germany, France, and the United Kingdom, the cost of CAR T-cell therapy can range from €300,000 to €350,000 per treatment. This price can vary based on the specific healthcare system's negotiation with pharmaceutical companies. For instance, in the United Kingdom, the National Health Service (NHS) negotiates the price of these therapies, which can lead to some variation in cost. In Germany, statutory health insurance typically covers the cost of these treatments, but the exact amount paid by the health system can differ based on negotiations.
It's important to note that these costs often cover more than just the CAR T-cell therapy itself. They include the entire treatment process, which involves the collection of a patient's cells, the modification of these cells in the laboratory, and the subsequent reinfusion into the patient.
Additionally, the price can encompass the necessary hospital stays, pre-treatment conditioning chemotherapy, and the management of potential side effects. Some European countries may have different approaches to financing these treatments, either through national healthcare systems, private insurance, or out-of-pocket payments by patients, which can also affect the overall cost faced by the patient.
Therefore, while the therapy itself has a high price tag, the actual cost to the patient can vary greatly depending on several factors, including the healthcare system and insurance coverage in their respective country.
Israel offers several good options for CAR-T therapy for lymphoma, leukemia, and multiple myeloma. Find out the cost in Israel.